Migraine.
Conditions
Interventions
Intervention group: Treatment with Magnesium Oxide tablet (9 mg/kg once daily)(39) + Riboflavin tablet (100 mg once daily)(30) for 8 weeks..
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Children aged 6 to 12 years with moderate to mild migraine headaches with or without aura Written informed consent to participate in the study Avoid taking medications that interact with magnesium oxide or riboflavin. No severe neurological disorders or epilepsy No hepatic, renal, gastrointestinal, cardiovascular, or metabolic disorders No tension headaches No history of sensitivity to magnesium oxide or riboflavin No renal failure
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average duration of migraine attacks. Timepoint: At the beginning of the study (before starting the intervention) and two months after treatment (end of the study). Method of measurement: Study data will be recorded using a researcher-made checklist that includes: age, sex, body mass index, migraine with and without aura, months since migraine onset, family history of migraine, and the average severity, frequency, and duration of headaches, dizziness, migraine disability criteria, along with the Pediatric Migraine Disability Assessment (PedMIDAS) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of migraine headache onsetFamily history of migraineFrequency of migraine headache attacksDuration of each episodeHeadache severityNauseaVomitingDizzinessMigraine Disability Assessment Questionnaire (PedMIDAS)Drug side effects. Timepoint: ?? ?????? ?????? (??? ?? ???? ??????) ? ?? ??? ?? ?? ????? (?????? ??????). Method of measurement: Study data will be recorded using a researcher-made checklist that includes: age, sex, body mass index, migraine with and without aura, months since migraine onset, family history of migraine, and the average severity, frequency, and duration of headaches, dizziness, migraine disability criteria, along with the Pediatric Migraine Disability Assessment (PedMIDAS) questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmehran ansarian
Shahre-kord University of Medical Sciences
Outcome results
None listed